Presentation Objectives
• Learn more about the prevalence and impact of hallucinations
and delusions associated with Parkinson's disease (PD)
psychosis, and the importance of routine screening
• Examine the therapeutic bind when managing both the motor
and nonmotor symptoms of PD
• Explore the clinical efficacy data and the safety profile of
NUPLAZID, the first and only FDA-approved treatment for
hallucinations and delusions associated with PD psychosis
• Review the support provided by Acadia Connect® to help
patients start and continue on NUPLAZID
